Last reviewed · How we verify
Euphorbia tablets
Euphorbia tablets is a Anti-inflammatory Small molecule drug developed by Panacea Biotec Ltd. It is currently in Phase 2 development for Treatment of wounds and skin ulcers. Also known as: To be confirmed later.
Euphorbia tablets are believed to have anti-inflammatory properties.
Euphorbia tablets are believed to have anti-inflammatory properties. Used for Treatment of wounds and skin ulcers.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Euphorbia tablets |
|---|---|
| Also known as | To be confirmed later |
| Sponsor | Panacea Biotec Ltd |
| Drug class | Anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of Euphorbia tablets is not well understood, but they are thought to exert their effects through the reduction of inflammation in the body.
Approved indications
- Treatment of wounds and skin ulcers
Common side effects
- Skin irritation
Key clinical trials
- Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (PHASE2, PHASE3)
- To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Euphorbia tablets CI brief — competitive landscape report
- Euphorbia tablets updates RSS · CI watch RSS
- Panacea Biotec Ltd portfolio CI
Frequently asked questions about Euphorbia tablets
What is Euphorbia tablets?
How does Euphorbia tablets work?
What is Euphorbia tablets used for?
Who makes Euphorbia tablets?
Is Euphorbia tablets also known as anything else?
What drug class is Euphorbia tablets in?
What development phase is Euphorbia tablets in?
What are the side effects of Euphorbia tablets?
Related
- Drug class: All Anti-inflammatory drugs
- Manufacturer: Panacea Biotec Ltd — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Treatment of wounds and skin ulcers
- Also known as: To be confirmed later
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing